Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Department of Internal Medicine I, University Clinic, RWTH Aachen University, Aachen, Germany.
Curr Heart Fail Rep. 2022 Dec;19(6):425-434. doi: 10.1007/s11897-022-00576-9. Epub 2022 Sep 27.
The distinction between 'acute' and 'chronic' heart failure persists. Our review aims to explore whether reclassifying heart failure decompensation more accurately as an event within the natural history of chronic heart failure has the potential to improve outcomes.
Although hospitalisation for worsening heart failure confers a poor prognosis, much of this reflects chronic disease severity. Most patients survive hospitalisation with most deaths occurring in the post-discharge 'vulnerable phase'. Current evidence supports four classes of medications proven to reduce cardiovascular mortality for those who have heart failure with a reduced ejection fraction, with recent trials suggesting worsening heart failure events are opportunities to optimise these therapies. Abandoning the term 'acute heart failure' has the potential to give greater priority to initiating proven pharmacological and device therapies during decompensation episodes, in order to improve outcomes for those who are at the greatest risk.
“急性”和“慢性”心力衰竭之间的区别仍然存在。我们的综述旨在探讨更准确地将心力衰竭失代偿重新分类为慢性心力衰竭自然史中的事件是否有可能改善结局。
尽管因心力衰竭恶化而住院会带来不良预后,但其中大部分反映了慢性疾病的严重程度。大多数患者在出院后的“脆弱阶段”死亡。目前的证据支持四类药物,这些药物已被证明可降低射血分数降低的心力衰竭患者的心血管死亡率,最近的试验表明,心力衰竭恶化事件是优化这些治疗的机会。放弃“急性心力衰竭”这一术语有可能在失代偿发作期间更优先考虑启动已证实的药物和器械治疗,以改善那些风险最高的患者的结局。